Home2024-01-20T15:11:17+00:00
Creating Oral Precision Oncology Therapies by Targeting Podoplanin

Sentrimed is an emerging biotech company developing novel, targeted therapies that exploit cell-to-cell communications essential to recognizing, immobilizing and eliminating abnormal cells. Our company is focused on:

Innovation icon
INNOVATION
Unique, IP protected assets targeting novel validated pathways critical to cancer progression
Patient icon
PATIENT-CENTRICITY
Biomarker driven oral medications focused on aggressive cancers with significant unmet needs
Impact icon
ENDURING IMPACT
Immobilize and eliminate tumor cells throughout the care continuum, alone or in combination with other agents
Go to Top